Searched for
RESPIRATORY PIPELINE
Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...- Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- COVID-19 had a scientific head start; the next pandemic virus may be a stranger. NVIDIA and Google DeepMind are using AI to map 2,800 viruses before the next outbreakAn international collaboration has developed a dataset of predicted protein structures from more than 2,800 viruses. This data is accessibl...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Cipla Q3 Results: Net profit plunges 57% YoY to Rs 676 croreCipla Q3 Results: Cipla reported a 57% YoY drop in net profit to Rs 676 crore, impacted by lower gRevlimid sales in North America. Despite ...
- Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ crCipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...
- Lupin shares in focus after $250 million U.S. facility plan; Citi retains buy callLupin plans a significant $250 million investment over five years to establish a new manufacturing facility in Coral Springs, Florida. This...
- Verona Pharma stock jumps 20% on $10B Merck deal—can FDA-approved Ohtuvayre reshape COPD care?Verona Pharma stock jumped 20% after Merck announced it will acquire the British biotech in a $10 billion deal. Merck will pay $107 per sha...
- Cipla makes additional investment in German mRNA biotechEthris' has four potential drugs under development pipeline, of which one is for treating uncontrolled asthma and three other for primary c...
- GSK Pharma to invest Rs 1,000 crore in Karnataka plantWe are investing Rs 1,000 crore in a new state-of-the- art pharmaceutical factory in Vemgal, Karnataka. The factory will initially supply a...
- Top five Indian pharma companies together spent over Rs 8000 crore on R&D spend in FY17The total R&D expenditure for the top five Indian companies has increased six-fold since FY10, bring the expense-to-revenue ratio in kilter...
- Neutral Cipla, target Rs 500: JPMorganJPMorgan sees challenges in the near-term with impact from restructuring in emerging markets. The ramp-up in US portfolio should help impro...
- Over 200 drugs under development, top 50 with $30 billion potential: CiplaElaborating on the pipeline for new drugs, Cipla said it has over 200 drugs under development with the top 50 projects having potential of ...
- Pharma MNCs like Johnson & Johnson, Novartis, step up India play with star drug launchesIn fact, pharma MNCs in India are growing faster than their local counterparts: according to AIOCD data, they expanded 13.8 per cent in Jul...
- Cipla announces commercial tie-up with UK's S&D PharmaPharmaceutical firm Cipla today announced commercial collaboration with UK-based S&D Pharma in the Czech Republic and Slovakia.
- Ex-Teva Frank Pieters to lead Cipla's European respiratory businessCipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...
Load More
